Cannabis has a long history of being used for a variety of purposes, from hemp oils and fibres to medicinal purposes. It became acknowledged and accepted into American pharmacopoeia, where it was evaluated for treating diseases, or the accompanying symptoms, until the early 1940s. In 1937, against the recommendation of the American Medical Association, the U.S. passed the first federal law against cannabis. Dr. William C. Woodward, testifying Read more about The Re-Education Of Medical Cannabis[…]
Last week, the Republican debate took a turn to focus on marijuana laws in the US. Moderator Jake Tapper took to a question popular on social media, asking about candidates views on marijuana legalization. He quoted Governor Christie, who recently said ‘if you’re getting high in Colorado today,’ where marijuana has been legalized, ‘enjoy it until January 2017, Read more about The Politics Of Medical Marijuana Takes Front Stage[…]
Dr. Nora Volkow, director of the National Institute on Drug Abuse, recently stepped forward to help clarify some of the misinformation circling marijuana and cannabidiol. As one of the world’s top experts on the application and misuse of cannabis and research, Volkow believes “what we can say with certainty is that cannabis contains active ingredients with potential therapeutic properties. In fact, the FDA has already approved medicines based on THC for the treatment of wasting syndrome and to control nausea in chemotherapy patients.”
While it may be a surprise to some that the FDA has actually approved products recognizing some of the positive aspects of THC, what shouldn’t come as a surprise is the support behind cannabidiol (CBD).
“There is also a great deal of interest in developing medications based on another constituent of the cannabis plant called cannabidiol” Volkow believes. “CBD, which does not give users the classic ‘high,’ has shown some promise in controlling seizures in children with severe forms of epilepsy (including Dravet and Lennox-Gastaut syndromes), and preliminary trials of a CBD-based drug are underway by GW Pharmaceuticals. There are likely many more applications for these other cannabinoids that are supported by a scientific rationale and some intriguing preliminary results that warrant more research.” […]
Last Friday, Michigan’s Medical Marijuana Review Panel voted to add autism to the list of qualifying conditions fit for treatment under state law.
Mike Zimmer, director of the Michigan Department of Licensing and Regulatory Affairs, is the next step in the process for approval. Zimmer has until late October to make a final decision. Once a final determination is made it will be announced on the agency’s website.
Supporters say using high CBD oil has been shown to help patients who suffer from severe autism, and added that the marijuana would not be given to patients in smokeable form.
The panel in charge of making this decision had the opportunity to listen to comments from some Detroit-area doctors, most notably the head of pediatric neurology at Children’s Hospital of Michigan. They also heard from fed up parents, desperate to find relief for their children.
“The parents I’ve talked to are passionate and adamant that this represents a dramatic improvement in the quality of life for them and their affected children,” said David Crocker, a medical marijuana doctor and member of the panel.
Michigan Lt. Gov. Brian Calley, whose daughter Reagan has autism, has been an advocate of the effort to add autism to the list. […]
Over the past few months, from local community halls to Capitol Hill, one thing has been made clear: there is an outcry of support in favor of more research on CBD and medical marijuana. Proponents of CBD oil state that removing these barriers to research is the only clear way to market something so significant to families around the world.
Earlier this year, Democrat Sen. Diane Feinstein (CA) and Republican Sen. Charles Grassley (IA) urged the Obama administration to “definitively determine if CBD has scientific and medical benefits,” and to “look at expanding compassionate access programs where possible, to benefit as many children as possible.”
Recently, support has also come out from the director of the US National Institute on Drug Abuse (NIDA), Nora Volkow. Volkow believes that cannabidiol (CBD) – a nonpsychotropic cannabinoid – is “a safe drug with no addictive effects.” In a column with The Huffington Post, she further stated that“[P]reliminary data suggest that it may have therapeutic value for a number of medical conditions.”
With all of the talk going on around the country, is there any action behind these promises? […]